- Human Biospecimens
- For Researchers
- For Biospecimen Contributors
- For Patients
February 16, 2017
Many of us love a good list – crisp, concise, actionable – and the internet abounds with Top Tens, Top Twenties and more. In terms of healthcare, list proliferation is vast, with everything from the top new cancer treatment approaches to the best hospitals in America. Products, services, trends – all are ripe for list development and user clicks abound. Case in point, a quick online search for healthcare lists brings up “top” performers and trends for medical devices, medical imaging, hospital marketing, and medical costs.
iSpecimen is joining the trendsetting and trendspotting ranks by participating on a keynote panel of medical innovators next week at the Cambridge HealthTech Institute’s Molecular Med Tri-Con event in San Francisco. The focus of the panel is “Emerging Technologies and Industry Perspectives” in molecular medicine. The session takes place Wednesday, Feb. 22, from 8:00-10:00am PST at the Moscone North Convention Center.
iSpecimen founder and chief executive officer Christopher Ianelli, MD, PhD, will detail our marketplace model for human biospecimen procurement, which will be essential for driving precision research, a necessary precursor to precision medicine. Scientists more than ever need a high-quality, diverse, and annotated supply of specimens that are selected just as precisely as the medicine we pursue.
Others in the session represent Genomic Healthcare Strategies, Lab7 Systems, Accel Biotech LLC, Boston Healthcare, Biocartis, SeraCare Life Sciences, NanoString Technologies and Menarini Silicon Biosystems.
If you’re going to Tri-Con, make sure to attend the session, and come chat with us in Booth 217. See you there!